Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 290-296

  Butler, Deborah ^a   Chen, Dongzhao ^b   O'Dwyer, Karen ^a   Lewandowski, Thomas ^a   Aubart, Kelly ^a   Zalacain, Magdalena ^c  

^a GLAXOSMITHKLINE   (United States)

^b WUXI APPTEC   (China)

^c Zala Drug Discovery Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMIKACIN; AMOXICILLIN; AZITHROMYCIN; GSK 1322322; GSK 466222; LINEZOLID; MOXIFLOXACIN; PEPTIDE DEFORMYLASE INHIBITOR; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ABSCESS; ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GROIN ABSCESS INFECTION; GROWTH INHIBITION; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; INFECTION; INGUINAL REGION; LOWER RESPIRATORY TRACT INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MURINAE; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; ENZYME INHIBITORS; HYDROXAMIC ACIDS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 84891544939     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01292-13     Document Type: Article

References (34)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770
2. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Patel PR, Fridkin SK. 2010. Health care-associated invasive MRSA infections, 2005-2008. JAMA 304:641-648. http://dx.doi.org/10.1001/jama.2010.1115
3. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687. http://dx.doi.org/10.1128/CMR.00081- 09
4. Adams JM. 1968. On the release of the formyl group from nascent protein. J. Mol. Biol. 33:571-589
5. Ball LA, Kaesberg P. 1973. Cleavage of the N-terminal formylmethionine residue from a bacteriophage coat protein in vitro. J. Mol. Biol. 79:531-537.
6. Livingston DM, Leder P. 1969. Deformylation and protein biosynthesis. Biochemistry 8:435-443. http://dx.doi.org/10.1021/bi00829a059.
7. Mazel D, Pochet S, Marliere P. 1994. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 13:914-923
8. Meinnel T, Blanquet S. 1994. Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA(fMet) formyltransferase. J. Bacteriol. 176:7387-7390
9. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J. 2000. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44:1825-1831. http://dx.doi.org/10.1128/AAC.44.7.1825-1831. 2000
10. Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45:2432-2435. http://dx.doi.org/10.1128/AAC.45.9.2432-2435.2001
11. Aubart K, Zalacain M. 2006. Peptide deformylase inhibitors. Prog. Med. Chem. 44:109-143. http://dx.doi.org/10.1016/S0079-6468(05)44403-3
12. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K. 2004. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. 53:664-668. http://dx.doi.org/10. 1093/jac/dkh129
13. Fritsche TR, Sader HS, Cleeland R, Jones RN. 2005. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49:1468-1476. http://dx.doi.org/10.1128/AAC.49.4.1468-1476 .2005
14. O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D. 2013. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob. Agents Chemother. 57:2333-2342. http://dx.doi.org/10.1128/AAC.02566-12
15. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: A randomized placebocontrolled study. J. Antimicrob. Chemother. 68:1901-1909. http://dx.doi .org/10.1093/jac/dkt097
16. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 57: 2005-2009. http://dx.doi.org/10.1128/AAC.01779-12
17. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Effect of H2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. Antimicrob. Agents Chemother. 57:2556-2561. http://dx.doi.org/10.1128/AAC.02505-12
18. Naderer OJ, Jones LS, Zhu J, Kurtinecz M, Dumont E. 2013. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. J. Clin. Pharmacol. 53: 1168-1176. http://dx.doi.org/10.1002/jcph.150
19. Qin D, Norton B, Liao X, Knox AN, Fang Y, Lee J, Dreabit JC, Christensen SB, Benowitz AB, Aubart KM. 2009. [(Pyrimidinylhydrazino)- 3-oxopropyl] hydroxyformamide derivatives as bacterial peptide deformylase inhibitors and preparation, pharmaceutical compositions and use in the treatment of bacterial infections. PCT Int. Appl. WO 2009061879 A1, scheme 25
20. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA
21. TM microbial cell viability assay. Technical bulletin. Promega Corporation, Madison, WI
22. Lowy FD 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532
23. Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: A global surveillance report (2003-2004). J. Antimicrob. Chemother. 57: 914-923. http://dx.doi.org/10.1093/jac/dkl093
24. Credito K, Lin G, Ednie LM, Appelbaum PC. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4033-4036. http://dx.doi.org/10. 1128/AAC.48.10.4033-4036.2004
25. Bowker KE, Noel AR, MacGowan AP. 2003. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int. J. Antimicrob. Agents 22:557-561. http://dx.doi.org/10. 1016/S0924-8579(03)00246-2.
26. Chen D, Hackbarth C, Ni ZJ, Wu C, Wang W, Jain R, He Y, Bracken K, Weidmann B, Patel DV, Trias J, White RJ, Yuan Z. 2004. Peptide deformylase inhibitors as antibacterial agents: Identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. 48:250-261. http://dx.doi.org/10.1128/AAC.48.1.250-261.2004.
27. Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS. 2009. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrob. Agents Chemother. 53:3777-3781. http://dx.doi.org/10.1128/AAC.00026-09
28. Adhikari RP, Novick RP. 2005. Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology 151:3059-3069. http://dx.doi.org/10.1099/mic.0. 28102-0
29. Gemmell CG, Ford CW. 2002. Virulence factor expression by Grampositive cocci exposed to subinhibitory concentrations of linezolid. J. Antimicrob. Chemother. 50:665-672. http://dx.doi.org/10.1093/jac/dkf192
30. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. 1998. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 42:2817-2823
31. Proctor RA, Olbrantz PJ, Mosher DF. 1983. Subinhibitory concentrations of antibiotics alter fibronectin binding to Staphylococcus aureus. Antimicrob. Agents Chemother. 24:823-826. http://dx.doi.org/10.1128/AAC.24.5.823
32. Rasigade JP, Moulay A, Lhoste Y, Tristan A, Bes M, Vandenesch F, Etienne J, Lina G, Laurent F, Dumitrescu O. 2011. Impact of subinhibitory antibiotics on fibronectin-mediated host cell adhesion and invasion by Staphylococcus aureus. BMC Microbiol. 11:263. http://dx.doi.org/10.1186/1471-2180-11-263
33. Kaplan JB. 2011. Antibiotic-induced biofilm formation. Int. J. Artif. Organs 34:737-751. http://dx.doi.org/10.5301/ijao.5000027
34. Haddadin RN, Saleh S, Al-Adham IS, Buultjens TE, Collier PJ. 2010. The effect of subminimal inhibitory concentrations of antibiotics on virulence factors expressed by Staphylococcus aureus biofilms. J. Appl. Microbiol. 108:1281-1291